期刊文献+

无血清培养的SP2/0细胞肿瘤学特性的研究 被引量:6

Investigation of Oncological Characters of SP2/0 Cells Cultivated in Serum-Free Medium
在线阅读 下载PDF
导出
摘要 目的:研究无血清培养条件下SP2/0细胞的相关肿瘤学特性。方法:应用MTT法检测用无血清培养所得的SP2/0细胞的增殖能力及这些细胞中SP细胞的比例,并检测它们的体内致瘤性。结果:SP2/0细胞在无血清培养基中增殖缓慢,但当把它们放回含血清培养中,则表现出比普通培养的SP2/0细胞有更高的增殖能力;无血清培养可以使SP2/0细胞中的SP细胞比例增加;无血清培养的SP2/0细胞比普通培养的SP2/0细胞在鼠体内有更高的体内致瘤性。结论:无血清培养可以增加SP2/0细胞中具有干细胞特性的瘤细胞比例,即可以富集SP2/0细胞的肿瘤干细胞。 Objective: To investigate the oncological characters of SP2/0 cells cultivated in serum-free medium. Methods: First, SP2/0 cells were cultivated in serum-free culture solution, then MTT colorimetry method, detecting SP cells, tumorigenesis experiment in BALB/c mice were respectively used to investigate their oncological characters. Results: SP2/ 0 cells proliferated slowly when they were cultivated in serum-free medium. However, when these cells were put back into serum-containing medium, they showed higher reproductive activity than that of SP2/0 cells cultivated in serum-containing medium did. Further, the ratio of SP cells were improved when SP2/0 cells were cultivated in serum-free medium. Last, SP2/0 cells that cultivated in serum-free medium gained higher oncogenicity in vivo. Conclusion: When cultivating in serum-free medium, the ratio of SP2/0 cells possessing the property of stem cells can be increased, what can also be said serum-free culture can enrich tumor stem cells in SP2/0 cells.
出处 《生物技术通讯》 CAS 2008年第1期20-23,共4页 Letters in Biotechnology
基金 东南大学国家自然科学基金预研项目
关键词 无血清培养 增殖能力 SP细胞 肿瘤干细胞 serum-free culture reproductive activity SP cells tumor stem cells
  • 相关文献

参考文献2

二级参考文献46

  • 1van der POL M A, FELLER N, ROSEBOOM M, et al. Assessment of the normal or leukemic nature of CD34 + cells in acute myeloid leukemia with low percentages of CD34 cells[ J ]. Haematologica, 2003,88(9): 983-993.
  • 2WUCHTER C, RATEI R, SPAHN G, et al. Impact of CD133(AC133) and CD90 expression analysis for acute leukemia immunophenotyping[ J ]. Haematologica, 2001,86( 2 ): 154-161.
  • 3VERCAUTEREN S M, SUTHERLANG H J. CD133 (AC133) expression on AML cells and progenitors[J]. Cytotherapy, 2001,3(6) :449-459.
  • 4AL-HAJJ M. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci U S A, 2003, 100(7):3983-3988.
  • 5SINGH S K, CLARKE I D, HIDE T, et al. Cancer stem cells in nervous system tumors[ J]. Oncogene, 2004, 23 (43): 7267-7273.
  • 6SINGH S K, HAWKINS C, CLARKE I D, et al. Identification of human brain tumour initiating cells [ J ]. Nature, 2004, 432(7015) :396-401.
  • 7CORBEIL D, ROPER K, HELLWIG A, et al. The human AC133hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions [ J]. J Biol Chem,2000, 275(8) :5512-5520.
  • 8YU Y, FLINT A, DVORIN E L, et al. AC133-2, a novel isoform of human AC133 stem cell antigen[J]. J Biol Chem,2002,277(23) :20711-20716.
  • 9FARGEAS C A, CORBEIL D, HUTINER W B. AC133 antigen,CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature [ J ]. Stem Cells,2003, 21(4) :506-508.
  • 10KOEHL U, ZIMMERMANN S, ESSER R, et al. Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia[J]. Bone Marrow Transplant, 2002, 29(11) :927-930.

共引文献27

同被引文献76

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部